Michael Bond is currently a Principal Scientist at GSK, part of the Oncology Innovation Team focusing on small molecule degrader discovery for oncology. They earned a Ph.D. in Pharmacology from Yale University after completing a Bachelor's degree in Molecular and Cell Biology and Chemical Biology at the University of Connecticut, where they graduated with honors. Prior to their current role, Michael worked as a Postdoctoral Researcher at Dana-Farber Cancer Institute, utilizing CRISPR and targeted protein degradation to explore pediatric cancer biology. Additionally, they gained research experience as an undergraduate researcher at Giardina Laboratory and Wright Laboratory, where they focused on drug target identification and chemical synthesis.
This person is not in the org chart
This person is not in any teams
This person is not in any offices